Theranostics was a privately held company founded in 2006. Its core technologies were focused on the quantitative measurement of proteins comprising key signaling pathways in disease and include pre-analytical processing of preclinical and clinical samples, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). The application of the technology enables TheraLink® to work with both freshly frozen and formalin-preserved research and clinical samples.
Company profile
Website
CEO
Michael I. Ruxin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
American Liberty Petroleum Corp., Oreon Rental Corp
SEC CIK
Corporate docs
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
13 May 19
8-K
Entry into a Material Definitive Agreement
9 Apr 19
8-K
Entry into a Material Definitive Agreement
26 Mar 19
10-Q
2019 Q1
Quarterly report
13 Mar 19
10-K
2018 FY
Annual report
1 Mar 19
8-K
Entry into a Material Definitive Agreement
6 Feb 19
10-Q
2018 Q3
Quarterly report
30 Jan 19
10-Q
2018 Q2
Quarterly report
9 Jan 19
10-Q
2018 Q1
Quarterly report
28 Dec 18
10-K
2017 FY
Annual report
4 Dec 18
Latest ownership filings
SC 13D
OncBioMune Pharmaceuticals, Inc
15 Jun 20
3
OncBioMune Pharmaceuticals, Inc
15 Jun 20
SC 13G
Avant Diagnostics, Inc
26 Oct 18
4
Jeffrey Busch
10 Oct 18
3
Andrew John DeLaO
21 Sep 18
3
RAJESH C MD SHROTRIYA
14 Sep 18
4
MICHAEL I RUXIN
11 Sep 18
3
Henry Cole
25 Jul 18
3
Jeffrey Busch
12 Jun 18
3
MICHAEL I RUXIN
5 Jun 18
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|